Skip to main content
. 2018 May 24;11:761–771. doi: 10.2147/IDR.S163280

Table 4.

ARs of mecillinam as monotherapy or combined with AMP

Reference Therapy Exanthema GI Others Total AR Total SAR
Frimodt-Møller and Ravn32 MEC or MEC/AMP 0 0 0 0/5 0/5
Ekwall et al30,a MEC/AMP, P-MEC/P-AMP 4 0 0 5/73 0/73
Ekwall et al30 MEC/P-MEC 1 0 0
Ode et al39 MEC/P-MEC 1 2 0 3/20 0/20
Trollfors et al38 MEC/P-MEC 0 0 0 0/25 0/25
Helin33 (pediatric) P-MEC 0 0 0 0/19 0/19
Eriksson et al31 MEC/AMP 7 4 5 16/43 0/43
Jernelius et al34 P-MEC/P-AMP 1 2 2 5/38 0/38
Jernelius et al34 (21 days) P-MEC/P-AMP 0 11 1 12/39 0/39
Cronberg et al29 MEC/AMP, P-MEC/P-AMP 12 15 5 32/144 0/144
Total Cumulative 26 34 13 73/406b (18%) 0/406 (0%)
Total MEC 2 2 0 4 0
Total MEC/AMP 24 32 13 69 0

Notes: We did not include the studies that did not report, specify, and/or categorize the side effects.

a

Half had double dose.

b

Some patients had more than one AR.

Abbreviations: AMP, ampicillin; AR, adverse reaction; GI, gastrointestinal; MEC, mecillinam; P-AMP, pivampicillin; P-MEC, pivmecillinam; SAR, serious adverse reaction.